ProKidney reports 2025 net loss $151.6M, cash $270M; Phase 3 PROACT 1 on track for mid-2026 enrollment

PROKIDNEY CORP.

Net loss $151.6M in 2025 vs $163.3M in 2024; no revenue as pre-revenue cell therapy company.
Cash and marketable securities $270.0M at Dec 31, 2025, down from $358.3M; runway into mid-2027.
Phase 3 PROACT 1 enrollment for accelerated approval (n~360) on track for mid-2026; top-line eGFR slope data Q2 2027.
FDA confirmed in July 2025 Type B meeting that eGFR slope can serve as surrogate endpoint for accelerated approval.
Positive Phase 2 REGEN-007 results presented at ASN Kidney Week 2025 and published in CJASN.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.